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Background: Imerslund-Gräsbeck Syndrome (IGS) is a rare genetic disorder characterised by juvenile megaloblastic
anaemia. IGS is caused by mutations in either of the genes encoding the intestinal intrinsic factor-vitamin B12 receptor
complex, cubam. The cubam receptor proteins cubilin and amnionless are both expressed in the small intestine as well
as the proximal tubules of the kidney and exhibit an interdependent relationship for post-translational processing and
trafficking. In the proximal tubules cubilin is involved in the reabsorption of several filtered plasma proteins including
vitamin carriers and lipoproteins. Consistent with this, low-molecular-weight proteinuria has been observed in most
patients with IGS. The aim of this study was to characterise novel disease-causing mutations and correlate novel and
previously reported mutations with the presence of low-molecular-weight proteinuria.
Methods: Genetic screening was performed by direct sequencing of the CUBN and AMN genes and novel identified
mutations were characterised by in silico and/or in vitro investigations. Urinary protein excretion was analysed by
immunoblotting and high-resolution gel electrophoresis of collected urines from patients and healthy controls to
determine renal phenotype.
Results: Genetic characterisation of nine IGS patients identified two novel AMN frameshift mutations alongside a
frequently reported AMN splice site mutation and two CUBN missense mutations; one novel and one previously
reported in Finnish patients. The novel AMN mutations were predicted to result in functionally null AMN alleles with no
cell-surface expression of cubilin. Also, the novel CUBN missense mutation was predicted to affect structural integrity of
the IF-B12 binding site of cubilin and hereby most likely cubilin cell-surface expression. Analysis of urinary protein
excretion in the patients and 20 healthy controls revealed increased urinary excretion of cubilin ligands including
apolipoprotein A-I, transferrin, vitamin D-binding protein, and albumin. This was, however, only observed in patients
where plasma membrane expression of cubilin was predicted to be perturbed.
Conclusions: In the present study, mutational characterisation of nine IGS patients coupled with analyses of urinary
protein excretion provide additional evidence for a correlation between mutation type and presence of the
characteristic low-molecular-weight proteinuria.
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Imerslund-Gräsbeck Syndrome or Megaloblastic Anaemia
1 (IGS or MGA1, OMIM #261100) is a rare, autosomal
recessive disorder characterised by selective intestinal vita-
min B12 malabsorption [1,2]. Most common clinical fea-
tures of the syndrome include megaloblastic anaemia,
failure to thrive, recurrent infections and selective low-
molecular-weight proteinuria [3]. IGS is a heterogenic
disorder caused by mutations in CUBN or AMN [4,5]. It
was originally described simultaneously in Norway and
Finland in 1960 [1,2] and since then, several hundred
cases have been reported worldwide [6]. A number of
these cases, however, may very likely represent misdiag-
nosed patients suffering from mutations of the gastric in-
trinsic factor gene (GIF) [7]. Both disorders, IGS and
hereditary GIF dysfunction, result in vitamin B12 defi-
ciency and are clinically very difficult to distinguish [6].
Especially, has the diagnosis of a group of IGS patients
presenting without proteinuria proved challenging to tell
apart from patients with juvenile dysfunction of GIF. Until
recently, these patients were clinically distinguished on
the basis of the so-called Schillings test [8] revealing any
deficiency in functional intrinsic factor. However, the test
is no longer available and the two groups of patients may
today only be correctly diagnosed through genetic ana-
lyses of the genes involved [6].
CUBN is located on chromosome 10 and encodes
cubilin (Figure 1B), also known as the intrinsic factor-
vitamin B12 (IF-B12) receptor [9,10] whereas AMN maps
to chromosome 14 and encodes amnionless (Figure 1B),
a 50 kDa, type 1 transmembrane protein [11]. Cubilin isFigure 1 Schematic presentation of the CUBN/AMN genes and transla
the CUBN and AMN genes. The previously described and novel CUBN misse
respectively. The novel AMN mutation deletion and insertion/deletion muta
previously described AMN founder mutation by an arrowhead. Exons are c
translated proteins for easy gene-to-function coupling. B: Domain organisa
CUB domains of cubilin are shown as grey and black eclipses. Intrinsic facto
furthermore highlighted. Amnionless is depicted with c-terminal membrana 460 kDa membrane-associated receptor protein com-
prising multiple ligand-binding CUB (Complement sub-
components C1r/s, Uegf, and Bmp 1) domains [12,13].
Together, cubilin and amnionless constitute the receptor
complex cubam, responsible for intestinal IF-B12 uptake
[14]. The IF-B12 binding site has been located to cubilin
CUB domains 5–8 [15] and recently the structural basis
for the interaction was established [16].
We and others have demonstrated a highly interdepen-
dent relationship of cubilin and amnionless for correct
processing and apical trafficking to the plasma membrane
[14,17-24]. So far, no transmembrane segment or endocy-
tic signals have been identified in cubilin [12]. Amnionless
however, harbours signals for receptor-mediated endo-
cytosis through clathrin-coated vesicles [14] and may
mediate internalization of the intestinal IF-B12 receptor
complex by engaging the clathrin-associated sorting pro-
teins disabled-2 (Dab2) and autosomal recessive hyper-
cholesterolemia (ARH) [25]. Cubilin and amnionless are
both highly expressed in the small intestine as well as the
proximal tubules of the kidney. In the latter, they function-
ally interact with the multi-specific endocytic receptor
megalin allowing the reabsorption of a panel of filtered
plasma proteins [26]. Cubilin is particularly important for
the normal tubular reabsorption of albumin [27,28], vita-
min D-binding protein (VDBP) [29,30], apolipoprotein
A-I (apo A-I) [31], and transferrin [32] but only the bin-
ding of albumin has been mapped to cubilin so far [33].
Several CUBN and AMN mutations have been re-
ported [24,34,35] since IGS was first reported in the
1960’s. Most reported mutations of the AMN gene mosttion products. A: Schematic presentation of the genomic structure of
nse mutations are indicated by a star and an enclosed star
tions are indicated by an enclosed bar and X respectively and the
olor-coded in grey scale to match the corresponding regions in the
tion in the two translation products cubilin and amnionless. EGF and
r-vitamin B12 binding region with identified missense mutations are
e association and extracellular cubilin interaction.
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site mutation in particular has been reported a number
of times in the Mediterranean region [5,36-38]. This mu-
tation changes the acceptor splice site of AMN intron 3
(c.208-2A>G) and causes skipping of exon 4, resulting in
a frameshift and premature stop codon in exon 6 [5].
Based on the established interdependent relationship of
cubilin and amnionless the AMN intron 3 mutation
most likely affects processing and trafficking of cubilin
although this remains to be demonstrated.
Investigations of a canine IGS model have furthermore
provided valuable insight into the role of amnionless in
this syndrome [20]. The IGS dogs suffer from functional
null mutations of the canine homologue to human AMN.
Immunohistochemical investigations of renal tissue from
these dogs showed that cubilin was not expressed at the
surface but retained in intracellular vesicles [20]. This
clearly illustrates a vital role of amnionless in normal cubi-
lin trafficking and membrane expression and furthermore
links mutations of AMN with intestinal malabsorption of
IF-B12.
The most prevalent mutation found in Finnish patients
(FM1) is a CUBN missense mutation changing the highly
conserved proline 1297 of cubilin CUB domain 8 to a leu-
cine [4]. This substitution results in decreased affinity of
the IF-B12 complex [39] hereby linking the underlying
genetic mutation with the intestinal malabsorption of
IF-B12 in these patients. In addition, a number of sporadic
CUBN null and missense mutations have also been identi-
fied [23,34,35]. However, the functional implications have
only been reported in two patients. A single cytosine for
guanine exchange in CUBN intron 23 (c.3330-439C>G,
originally described as IVS-intra CUB6 C>G, FM2) was
found to trigger complex splicing, resulting in premature
truncation of the receptor protein [4]. In addition, we re-
cently investigated another sporadic CUBN mutation in
an Italian family [23]. The mutation changed the highly
conserved donor splice site of exon 23 most likely resul-
ting in aberrant splicing and functionally null CUBN
alleles. Accordingly, no cubilin was detected in renal tissue
from this patient [23].
Recently, we established that the molecular background
for the low-molecular-weight proteinuria observed in
these patients is due to proximal tubular dysfunction of
cubilin [23]. Immunohistochemical investigations of renal
tissue from a cubilin-deficient patient revealed an abnor-
mal distribution of the receptor partner amnionless as well
as reduced uptake of the selective cubilin ligand apo A-I.
Furthermore, analyses of the urinary protein excretion in
this patient revealed increased urinary excretion of the
cubilin ligands transferrin, apo A-I, VDBP, and albumin as
previously reported [28,30-32,40]. Consistent with obser-
vations from the dogs suffering from mutations of the ca-
nine AMN homologue, low-molecular-weight proteinuriahas also been reported in IGS patients with AMN muta-
tions [24,36-38].
Interestingly, the characteristic low-molecular-weight
proteinuria has not been consistently observed in IGS
patients [40]. Correlation between the specific disease-
causing mutations and the low-molecular-weight protein-
uria has not been established so far but accumulating
evidence indicates that functional null mutations of both
CUBN and AMN may result in low-molecular-weight pro-
teinuria contrasting observations from patients with the
FM1 missense mutation [24,36-38,40].
In the present study, genetic screening of nine IGS
patients identified two previously described disease-
causing mutations as well as three novel mutations,
including two AMN null mutations and one CUBN mis-
sense mutation. Functional investigations of the novel
mutations predicted them to result in dysfunctional
membrane expression of cubilin. Low-molecular-weight
proteinuria was only identified in patients where cubilin
was predicted to be absent from the cell surface, thus,
providing additional evidence for a correlation between
the nature of the genetic mutations and the characte-
ristic urinary protein excretion observed in most of these
patients.
Methods
Patients
Informed consent for genetic testing was obtained from
all the families included in this study. This study was
approved by the Central Denmark Region Committee on
Biomedical Research Ethics and conducted in accor-
dance with the Declaration of Helsinki. Genomic DNA
was isolated from peripheral blood using standard pro-
cedures for direct genomic sequencing of CUBN and
AMN genes. Diagnosis of selective intestinal vitamin B12
malabsorption (IGS or MGA1) was based on previously
established criteria [6]. For detailed patient information
see Additional file 1. Family information is given in
Table 1.
Mutation analyses
Nucleotides are numbered according to GenBank accession
numbers [NM_001081.3] (CUBN) and [NM_030943.3]
(AMN) with +1 corresponding to the A of the ATG trans-
lation initiation codon and the initiation codon cor-
responding to codon 1. CUBN and AMN exons, with
flanking intronic regions, were amplified using standard
PCR procedures with sequence specific primers (primer
sequences are available upon request) and a polymerase
(HOT FIREPol® DNA polymerase; Solis Biodyne, Estonia).
AMN exons were amplified in 7 fragments with addition
of the PCR additive S-Solution for amplification of GC-
rich templates. Amplified products were enzymatically
purified (ExoSAP-IT; USB Corporation, Cleveland, Ohio,
Table 1 Family information
Family Consanguineousparents
Ethnic
origin
Number
of affected
children
AMN
Family 1
yes Turkish 1c.208-2A>GA/c.208-2A>GA
(p.Leu70Alafs)
Family 2
yes Tunesian 2c.208-2A>GA/c.208-2A>GA
(p.Leu70Alafs)
Family 3
yes Moroccan 1
c.1006 + 11_1008del/
c.1006 + 11_1008del
(p.Glu337Asnfs)
Family 4
no Italian 2
c.1041_1042delinsCTC/
c.208-2A>GA
(p.Glu348Serfs/p.Leu70Alafs)
CUBN
Family 5
yes Tunesian 2c.3335G>A/c.3335G>A
(p.Gly1112Glu)
Family 6
no Finnish 1c.3890C>T/c.3890C>TB
(p. Pro1297Leu)
Table 1 summarises the families included in the study with identified
mutations, family background and number of affected children.
APreviously described as c.208-2A>G, skipping of exon 4, fs [5]. BPreviously
described by [4]. Paternal/maternal allele.
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(Big Dye® Terminator v1.1 Cycle Sequencing Kit;
Applied Biosystems, Naerum, Denmark). Sequencing
products were purified using pre-soaked Sephadex G-
50 (GE Healthcare Orsay, France) 96-well multiscreen
filter plates (Millipore, Molsheim, France). Purified
products were analysed on an automated 48-capillary
sequencer (ABI 3730 Genetic analyser; Applied Biosys-
tems, Courtaboeuf, France) and the results interpreted
using the SeqScape® software (Applied Biosystems).
Novel sequence variants were compared to commer-
cially available control alleles (Human random control
panels; Health Protection Agency Culture Collections,
Salisbury, United Kingdom) to exclude commonly oc-
curring polymorphisms. In silico splicing prediction
analyses was performed using the NNSPLICE server
(0.9 version) (http://fruitfly.org/seq_tools/splice.html).
No additional patient material was available for ana-
lyses of AMN splicing.Established constructs
The genomic fragments comprising AMN exon 8 to
exon 12 (c.782-1327) were amplified through PCR from
a healthy control subject and the index patient of family
3 (homozygous for c.1006 + 11_1008del) using the fol-
lowing AMN specific primers; 5′-CCCTCCCGCTAGCA
TGGCCGTTGTGTTGCTGACCCA-3′ containing the
NheI restriction site and an in frame ATG start codon
and primer 5′-ATTCCCCTCGAGTCATGACGAAGT
AACTGTGGCTGGT-3′ containing the Xho I restric-
tion site and an in frame TGA stop codon. Amplifi-
cation products were cloned into expression vectors
(pcDNA™ 3.1(+); Invitrogen, Taastrup, Denmark) using
NheI-HF™ and Xho I restriction enzymes (New England
Biolabs, Medinova Scientific A/S, Glostrup, Denmark) ac-
cording to manufacturer’s guidelines (wt gAMN8-12 and
del gAMN8-12) and subsequently transformed into com-
petent cells (One Shot® TOP10; Invitrogen) for propa-
gation. CHO-K1 cells were transiently transfected with
either wt gAMN8-12 or del gAMN8-12 plasmids in dupli-
cates and total RNA was isolated 48 hours after transfec-
tion (RNeasy Mini Kit; Qiagen, Ballerup, Denmark).
Splicing was analysed by RT-PCR (OneStep RT-PCR kit;
Qiagen) using primers 5′-CACCTTCCTGGGTCTGCC
TCAGTACC-3′ and 5′-GGCGCCACCAGCAGGACCA
GCA-3′ according to manufacturer’s protocol. cDNA
amplification products were cloned into vectors (pCR®II-
TOPO® using TOPO TA cloning technique, Invitrogen)
according to manufacturers protocol for subsequent
sequencing.
The c.3335G>A (p.Gly1112Glu) identified in family 5,
was introduced into a previously described fragment of
human cubilin, encoding CUB domains 5–8 [39], through
site-directed, ligase-independent mutagenesis (SLIM)[41]
using the following primers (Ft: 5′-CAGAGATGAAGGC
TATGAAAAATCACCATTGCTGGG-3′; Rt: 5′-TCA
TAGCCTTCATCTCTGATTTCCAGAAAATCTGTA-3′;
Fs: 5′-AAAATCACCATTGCTGGG-3′; Rs: 5′-ATTTC
CAGAAAATCTGTA-3′). Whole plasmid amplification
was carried out in one reaction using a polymerase
(Herculase II fusion polymerase; AH Diagnostics a/s,
Aarhus, Denmark) with subsequent digestion of template
strands and rehybridisation as previously described [41].
Plasmids were subsequently transformed into competent
cells (One Shot® TOP10, Invitrogen) for propagation.Cell propagation and transfection
CHO-K1 cells were grown in HyQ-CCM5 (HyClone,
Logan, UT, USA) serum free growth medium containing
100 units/ml penicillin and 100 μg/ml streptomycin and
transiently transfected with plasmids using the Lipofec-
tamine™ 2000 (Invitrogen) according to manufacturer’s
protocol.
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medium
Growth medium was collected from propagated cells
prior to lysis and centrifuged at 2,000 g for 2 min. Super-
natant was transferred to a new tube, sample buffer
added and concentrated for 50 min at 95°C. Cells were
washed twice with PBS buffer pH 7.4 and subsequently
lysed using a Triton X-100 (Merck, Denmark, Industrial
Chemicals & Pigments, Hellerup, Denmark) and EDTA-
free protease inhibitor (Complete; Roche, Hvidovre,
Denmark) containing buffer. Cell lysates were centri-
fuged at 4,000 g for 5 min and supernatants collected.
Growth medium and cell lysates were subsequently ana-
lysed using SDS-PAGE and immunoblotting.
Urine analyses
Urine samples (24-hour urine or spot urine) obtained
from the patients were frozen at −80°C after collection.
Urinary protein excretion was normalised using urinary
creatinine concentrations and compared with urines
collected from 20 young, healthy subjects (aged 3–
7 years). The urinary excretion of a certain ligand was
defined as increased when all of the controls despite
variability had excretion levels below the excretion
levels observed in patients. Urinary protein excretion
was evaluated through immunoblotting or using the
Sebia High-Resolution Gel Electrophoresis System
(Sebia, Evry, France) according to the manufacturer’s
instructions. Urine samples were applied on high reso-
lution gels for urine analysis (Hydragel 5 proteinuria;
Sebia) and processed using the Hydrasys 2 instrument
(Sebia).
Immunoblotting
Proteins were separated by SDS-PAGE and transferred
to an ImmobilonTM–FL PVDF transfer membraneTable 2 Functional characterisation of identified IGS causing
Family Gene Genomicregion
Protein
prediction
Mutation
type
AMN
1 and 2 c.208-2A>GA/c.208-2A>G Intron 3 p.Leu70Alafs Frameshift
3
c.1006 + 11_1008del/
Intron 9 p.Glu337Asnfs Frameshift
c.1006 + 11_1008del
4
c.1041_1042delinsCTC/ Exon 10/ p.Glu348Serfs/ Frameshift/ E
c.208-2A>GA intron3 p.Leu70Alafs Frameshift
CUBN
5 c.3335G>A/c.3335G>A Exon 24 p.Gly1112Glu Missense
6 c.3890C>T/c.3890C>TB Exon 27 p.Pro1297Leu Missense
Table 2 summarises functional characterisation and protein predictions of the ident
molecular-weight proteinuria, prediction of cubilin membrane expression and recep
megalin ligands in patient urines using immunoblotting or high-resolution gel elect
silico protein predictions.APreviously described as c.208-2A>G, skipping of exon 4, fs
by [39].(Millipore, Copenhagen, Denmark) using the iBlot™ Dry
Blotting System (Invitrogen). Membranes were
subsequently blocked and incubated with primary and
fluorophore-coupled secondary antibodies according
to manufacturer’s instructions (LI-COR Biosciences,
Cambridge, United Kingdom). Proteins were detected
using the Odyssey™ infrared imager (LI-COR
Biosciences).
Antibodies
(Primary) rabbit anti vitamin D-binding protein (Dako,
Glostrup, Denmark), rabbit anti transferrin (Dako), rabbit
anti apo A-I (Dako), rabbit anti albumin (Dako), rabbit
anti α1-M (Dako), rabbit anti retinol-binding protein
(RBP) (Dako), rabbit anti human cubilin (kindly provided
by Søren K. Moestrup, Institute of Biomedicine, Aarhus
University, Denmark) (Secondary) goat anti-rabbit IRDye®-
800 CW (LI-COR Biosciences, Lincoln, Nebraska USA).
Results
Mutation analyses
Direct sequencing of the CUBN and AMN genes in six
affected families (1–6) (Table 1) revealed two novel
mutations of the AMN gene (Family 3 and 4) and one
novel mutation of the CUBN gene (Family 5). In families
1 and 2 a homozygous mutation of the AMN intron 3
acceptor splice site was identified (c.208-2A>G). This
mutation was originally reported in families of Tunisian
Jewish and Turkish origin as c.208-2A>G, skipping of
exon 4; fs [5,34] and causes complete skipping of exon 4
resulting in a frameshift and a premature stop codon
(Table 2).
In family 3, direct sequencing revealed a homozygous
70 bp deletion of AMN intron 9 (c.1006 + 11_1008del)
with a resulting elimination of the AMN exon 10 splice
acceptor site (Figure 1A) (Table 1). No alternativemutations
Protein region Low–molecular-weightProteinuria
Predicted cubilin
cell-surface expression
Extracellular domain Yes* NoA
Extracellular domain Yes* No† and ♦
xtracellular domain/
Yes* No♦
Extracellular domain
CUB 6 Yes* No† and ♦
CUB 8 (no)* YesC
ified mutations including mutation classification, observations of low-
tor function. *Based on analyses of urinary excretion of selective cubilin and
rophoresis, see Table 3. †Based on in vitro functional analyses. ♦Based on in
[5]. BPreviously described by [4]. CFunctional analyses previously described
Figure 2 Sequencing analysis of (c.1006 + 11_1008del) gAMN8-12 minigene mRNA transcript. A selected region of the trace data,
obtained from RT-PCR analyses of purified mRNA from transiently transfected CHO-K1 cells with the established (c.1006 + 11_1008del) gAMN8-12
minigene construct, showed incorporation of 10 base pairs of AMN intron 9 in the spliced mRNA product. Arrow indicates point of the 70 bp
deletion. Coding and intron sequence is represented by upper and lower case letters, respectively. The open reading frame (ORF) for normally
spliced AMN mRNA in this region is shown below with the resulting altered reading frame for c.1006 + 11_1008del highlighted in red.
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or exon 10 using the NNSPLICE server (0.9 version). RT-
PCR and cDNA sequencing of total RNA isolated from
CHO-K1 cells expressing either genomic wt AMN exon
8–12 or AMN exon 8–12 (c.1006 + 11_1008del) showed
abrogated splicing with retention of the remaining 10 bp
of intron 9 in the mutant mRNA transcript (Figure 2).
The deletion consequently causes a translational frame-
shift and a premature stop codon most likely resulting in
nonsense mediated decay of the aberrant mRNA and thusFigure 3 G1112 is located in the tight interface between CUB 5, 6 and
complex with IF (PDB accession 3KQ4) [16]. The CUB domains are illustrate
residue is located in the interface between CUB domains 5, 6 and 7 and sh
domains 5, 6 and 7. Residues lining the interface are here indicated in gree
transparent surface. This clearly shows that G1112 is centrally located withi
polar residue could potentially cause severe sterical clash with surrounding
generated using Visual Molecular Dynamics [43].functional AMN null alleles (Table 2). Consistent with
this, both parents were heterozygous at this position and
the 70 bp deletion was not detected in 158 control alleles.
Direct sequencing, of the AMN gene in family 4,
revealed compound heterozygous mutations in the two
affected children (Table 1). In both patients the c.208-
2A>G mutation, described above, was observed on
the maternal allele whereas a novel deletion-insertion
of exon 10 (c.1041_1042delinsCTC) was identified on
the paternal allele (Figure 1A). The insertion-deletion7. A: Overview of the structure of cubilin CUB domains 5–8 in
d in green cartoons and IF domains in blue cartoons. The G1112
own as red spheres. B: Zoom-view of the interface between CUB
n sticks. The space occupied by the interface residues is indicated by a
n the tight interface and accordingly, that a substitution to a larger and
residues as well as disturb inter-domain interactions. The figure was
Figure 4 Immunoblotting of conditioned growth medium (A)
and cell lysates (B) from CHO-K1 cells transiently transfected
with wt or Gly1112Glu CUB 5–8 cubilin. Proteins were separated
using SDS-PAGE (3–8%). and transferred to an Immobilon™ –FL PVDF
transfer membrane using the iBlot™ Dry Blotting System. CUB 5–8
proteins were detected with a rabbit anti human cubilin antibody
and visualised using LICOR IRDye λ 800 goat a-rabbit. Immunoreac-
tive bands, consistent with the size of recombinant cubilin CUB 5–8,
are indicated with white asterisks. No mutant CUB 5–8 protein was
detected in the conditioned growth medium in contrast to the wt
CUB 5–8 protein as previously described [39]. Both the wt and mu-
tant protein were detected in cell lysates.
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stop codon could be detected upstream of the AMN 3′
UTR region (Table 2). Due to the aberrant and elongated
AMN transcript product, the c.1041_1042delinsCTC
may result in an unstable amnionless protein and thus
in functional null alleles. The mutation was not seen in
166 control alleles.
In family 5, a novel missense mutation of CUBN exon
24 was identified (c.3335G>A, p.G1112E) (Figure 1A and
B) (Table 1). CUBN exon 24 partly encodes CUB domain
6, part of the IF-B12 binding site in cubilin [15,16]. The
mutation changes the fully conserved, small, non-polar
residue glycine 1112 to a large, polar glutamate and was
not detected in 350 control alleles. Glycine 1112 is located
in loop 6 of CUB domain 6 near the interfaces of CUB
domains 5, 6 and 7 [16] (Figure 3A and B). The interfaces
are here dominated by Van der Waal’s interactions indi-
cating that the introduction of a polar glutamate residue
in this region could affect the structural integrity of the
interacting CUB domains [16]. Consistent with this, intro-
duction of the glutamate residue in this region was found
to be probably damaging with a score of 1.0 by PolyPhen-
2 v2.1 [42].
Cubilin CUB domains 5–8 [39] were expressed in two
variants in CHO-K1 cells, a wild-type and a G1112E
mutant form. Immunoblotting analyses of conditioned
growth medium and cell lysates from CHO-K1 cells tran-
siently transfected with wt or G1112E CUB 5-8 showed
that the wt CUB 5-8 protein was secreted to the growth
medium (Figure 4A) as previously reported [39]. However,
the G1112E CUB 5-8 was only observed in cell lysates
(Figure 4B) indicating that the mutant cubilin fragment is
retained in intracellular compartments. This hereby sug-
gests that the G1112E mutation identified in family 5 may
have detrimental effects on the structural integrity of full
length cubilin, possibly resulting in impaired processing
and decreased or absent cell-surface expression of cubilin.
Therefore, intestinal IF-B12-absorption in individuals of
family 5 would probably be affected (Table 2).
Finally, direct sequencing revealed a homozygous
missense mutation in CUBN exon 27 (c.3890C>T, p.
P1297L) in the patient of family 6 (Figure 1B) (Table 1).
This mutation has previously been reported in families
of Finnish origin [4] and reduces IF-B12 complex recog-
nition by cubilin (Table 2) [39].
Urine analyses
Immunoblotting or high-resolution gel electrophoresis of
urine collected from the patients of families 1–5 showed
increased urinary excretion of the cubilin ligands; trans-
ferrin, apo A-I, albumin, VDBP, and α1-microglobulin
(α1-M), recently described as a novel ligand of cubilin
(Table 3) [23]. In line with a previous report of urinary
protein excretion in FM1 patients [40], analyses of urinaryprotein excretion in the index patient of family 6 did not
show clearly increased urinary excretion of albumin,
transferrin or VDBP (Table 3). Also, no increased urinary
excretion of the megalin ligand RBP was observed in the
patient urines consistent with an isolated tubular cubilin
dysfunction.
Discussion
In the present study, we identified two novel mutations
of the AMN gene and one novel mutation of the CUBN
gene as well as three previously described disease-
Table 3 Urinary protein excretion
Mutation Albumin Transferrin VDBP Apo A-I α1-M RBP
AMN
c.208-2A>G/c.208-2A>GA
x x x No + x x No
(p.Leu70Alafs)
c.1006 + 11_1008del/c.1006 + 11_1008del
x x x x x No
(p.Glu337Asnfs)
c.1041_1042delinsCTC/c.208-2A>GA
x x x x x No
(p.Glu348Serfs/p.Leu70Alafs)
CUBN
c.3335G>A/c.3335G>A
x x x x x No
(p.Gly1112Glu)
c.3890C>T/c.3890C>TB
(x) (x) (x) (x) (x) No
(p.Pro1297Leu)
Table 3 summarises the urinary protein excretion in the six families according to identified mutations. Urines were analysed by immunoblotting or high-resolution
gel electrophoresis for urinary protein excretion of the cubilin ligands albumin, transferrin, VDBP, Apo A-I, α1-M as well as a selective ligand of megalin, RBP.
Increased urinary excretion of the listed proteins is indicated with an x and with (x) if only trace amounts were observed. No + x indicates that not all the affected
patients with this mutation showed similar increased urinary excretion.
APreviously described as c.208-2A>G, skipping of exon 4, fs [5]. BPreviously described by [4].
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patients from six families. In addition, we performed a
detailed analysis of the urinary protein excretion in these
patients and investigated effects on receptor function
through in silico and/or in vitro analyses. Table 2 sum-
marises the functional characterisations of the detected
mutations.
It was previously proposed that downstream putative
transcription start sites of the AMN gene were responsible
for the non-lethal phenotype of IGS patients with AMN
mutations in the 5′ region [5] in contrast to the embry-
onic lethality observed in Amn-deficient mice [11]. How-
ever, this does not appear to be the case as subsequent
reports have identified mutations farther downstream in
the AMN gene [34]. Instead, it may represent essential dif-
ferences in embryonic development of humans and mice
[44,45]. Human studies of IGS are therefore crucial for
understanding the underlying molecular pathology of the
clinical manifestations in these patients. This is, however,
very difficult due to lack of accessible cubilin- and
amnionless-expressing tissues.
In families 1 and 2 we identified the previously des-
cribed c.208-2A>G mutation of the AMN gene. Both fami-
lies originate from the Mediterranean region (Table 1)
where this mutation was previously reported a number of
times [5,36-38]. Identification of this mutation in add-
itional families hereby provides further evidence of a
founder effect originating from this region [34,46]. The
70 bp intronic deletion of the AMN gene identified in
family 3 is to our knowledge the largest deletion reported
in an IGS patient so far and most likely results in func-
tionally null AMN alleles. Compound heterozygous muta-
tions of the AMN gene have not been frequently reported[24,35,47,48] but here we report an additional case of a
compound heterozygous mutation of the AMN gene. In
family 4, c.208-2A>G was identified on the maternal
allele whereas a novel deletion-insertion of exon 10
(c.1041_1042delinsCTC) was identified on the paternal
allele. To our knowledge, this is also the first report of an
insertion-deletion mutation in an IGS patient, thus adding
to the heterogeneity of the syndrome. Similar to the 70 bp
deletion identified in family 3, the deletion-insertion most
likely results in a functional null AMN allele. Both the pre-
viously described Mediterranean founder mutation and
the novel AMN mutations most likely affect cell surface
expression of cubilin (Table 2), as posttranslational modi-
fications and apical membrane expression of cubilin is
highly dependent on proper amnionless function and lo-
calisation [17,18,20,28].
Genetic screening of family 5 and 6 revealed two dis-
tinct missense mutations of the CUBN gene. Family 6 is
of Finnish origin and here, the previously described FM1
mutation was identified in the affected child. In family 5,
however, a novel missense mutation of CUBN exon 24
(c.3335G>A, p. G1112E) was identified. The affected
residue is located in CUB domain 6 which is part of the
IF-B12 binding site of cubilin [15,16]. Functional analyses
of the G1112E mutation showed intracellular retention
of the mutant protein in transfected CHO-K1 cells, most
likely caused by detrimental effects on structural integ-
rity of the CUB domain interactions (Table 2). Despite
the seemingly similar nature of the two CUBN muta-
tions, the functional analyses predict highly distinctive
effects on receptor function. This prediction is consis-
tent with the observed differences in urinary protein ex-
cretion in the affected patients from the two families
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of Finnish origin (FM1, P1297L) did not show a clear in-
crease in urinary excretion of cubilin ligands (Table 3)
[40]. Although previous in vitro studies of P1297L sug-
gest that the mutation does not affect the structural in-
tegrity of the IF-B12 binding site of cubilin [39], limited
amounts of cubilin ligands were detected in the urine of
this patient. As the interaction sites of very few cubilin
ligands have been mapped it is likely that these may have
overlapping interaction sites with IF-B12.Thus, this could
possibly result in decreased affinity for more cubilin
ligands besides IF-B12 and consequently also in a slightly
less efficient proximal tubular function of cubilin.
In contrast, increased urinary excretion of the cubilin
ligands; albumin, transferrin, VDBP, apo A-I and α1-M
was detected in the patients of family 5. This is in line
with observations from the patient identified with the
IVS-intraCUB6 C>G, FM2 CUBN mutation [30-32,40].
Consistent with predictions of disrupted cubilin mem-
brane expression, increased urinary excretion of cubilin
ligands was also observed in the patients with AMN
mutations (Table 3).
Thus, the observations presented here provide addi-
tional evidence supporting a correlation between the
nature of the IGS-causing mutation and the presence of
low-molecular-weight proteinuria. Combined with pre-
vious reports of low-molecular-weight proteinuria in
IGS patients [24,35-38,40] this constitutes a solid basis
for classifying identified IGS causing mutations as either;
1) mutations affecting only receptor recognition of
IF-B12 in the small intestine or 2) mutations of CUBN or
AMN affecting the overall expression of cubilin on the
cell surface resulting in both intestinal IF-B12 malabsorp-
tion and decreased proximal tubular reabsorption of
cubilin ligands from the glomerular ultrafiltrate.
Interestingly, Tanner and co-workers did not identify
any IGS-causing mutations beyond CUBN exon 28 (cor-
responding to cubilin CUB domain 8) in a recent large
genetic study of families with inherited malabsorption of
cobalamin [48]. Furthermore, a recent report described
a novel single base pair deletion in CUBN exon 53
(c.8355delA; p.S2785fsX19, corresponding to cubilin CUB
domain 20) causing only albuminuria but not megalo-
blastic anaemia [49]. The functional consequences of this
particular exon 53 single base pair deletion were not
investigated but a similar mutation was recently reported
in a group of border collies affected with IGS [50]. De-
tailed investigations of the cubilin expression and function
in these dogs identified reduced expression of cubilin and
no evidence of a stable truncated cubilin protein. The vita-
min B12 status of the patients harbouring the c.8355delA
mutation was not analysed in detail but based on the func-
tional investigations in the dog model, it is likely that the
patients are deficient in vitamin B12 despite the absence ofmegaloblastic anaemia. Both patients are under 5 years of
age and late onset IGS has been reported multiple times
in the literature [3]. Because CUB domains 22–27 bind
megalin in vitro [51] and numerous studies have estab-
lished that megalin is essential for the endocytic function
of cubilin in the proximal tubules [52], one might still
speculate, however, that CUBN variations in this particular
region, resulting in a stable cubilin protein, could consti-
tute a third group of CUBN variations that affects only
proximal tubular function of cubilin without affecting the
intestinal function. Thus, it may be possible that certain
CUBN mutations may lead to a cubilin related proteinuria
without causing IGS. However, based on the current avail-
able data, this remains purely speculative and clearly, addi-
tional research is needed to further elucidate this.
Conclusions
In conclusion, the data presented here provide novel insight
into the molecular mechanisms underlying the pathology
of intestinal IF-B12 malabsorption and low-molecular-
weight proteinuria of IGS. They furthermore provide add-
itional evidence for a correlation between the nature of the
individual disease-causing mutation and the presence of
low-molecular-weight proteinuria in IGS patients.Additional file
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